M3 muscarinic acetylcholine receptor in cardiology and oncology

International Journal of Cardiology

Volumn 177, Issue 2, 2014, Pages 646-649

  Patanè, Salvatore ^a  

^a Cardiologia Ospedale San Vincenzo   (Italy)

Author keywords

Arrhythmias; Cardio oncology; EGFR; HERG; Ischemia; M3 muscarinic receptor (M3 mAChR)

Indexed keywords

MUSCARINIC M3 RECEPTOR;

ANIMAL; CARDIOLOGY; CARDIOVASCULAR DISEASE; HUMAN; NEOPLASM; ONCOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRENDS;

ANIMALS; CARDIOLOGY; CARDIOVASCULAR DISEASES; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RECEPTOR, MUSCARINIC M3;

EID: 84913550571     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.09.178     Document Type: Article

References (97)

1. A. Daliry, I.S. Caldas, Diniz L. de Figueiredo, R.M. Torres, A. Talvani, and M.T. Bahia Anti-adrenergic and muscarinic receptor autoantibodies in a canine model of Chagas disease and their modulation by benznidazole Int J Cardiol 170 3 Jan 1 2014 e66 e67
2. W.C. Tsai, T.I. Lee, Y.C. Chen, Y.H. Kao, Y.Y. Lu, and Y.K. Lin Testosterone replacement increases aged pulmonary vein and left atrium arrhythmogenesis with enhanced adrenergic activity Int J Cardiol 176 1 Sep 2014 110 118
3. K. Hishikari, T. Kuwahara, A. Takahashi, and M. Isobe Severe coronary artery spasm during radiofrequency ablation for atrial fibrillation Int J Cardiol 172 3 Apr 1 2014 e513 e515
4. J.W. Petersen, P.K. Mehta, T.S. Kenkre, R.D. Anderson, B.D. Johnson, and C. Shufelt Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Int J Cardiol 172 1 Mar 1 2014 e114 e115
5. J. Winter, K.E. Brack, J.H. Coote, and G.A. Ng Cardiac contractility modulation increases action potential duration dispersion and decreases ventricular fibrillation threshold via β1-adrenoceptor activation in the crystalloid perfused normal rabbit heart Int J Cardiol 172 1 Mar 1 2014 144 154
6. 2 receptor stimulation is athero-protective and stabilizes plaque in apolipoprotein E-deficient mice Int J Cardiol 169 4 Nov 15 2013 281 287
7. D. Matsumoto, T. Shinke, T. Nakamura, J. Shite, J. Li, and D. Hou Optical coherence tomography and histopathological assessment of delayed arterial healing after drug-eluting stent implant in a pig coronary model Int J Cardiol 170 2 Dec 10 2013 152 159
8. X. Li, J. Han, L. Li, K.J. Wang, and S.J. Hu Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats Int J Cardiol 168 4 Oct 9 2013 3340 3347
9. K. Tsujita, K. Sakamoto, S. Kojima, S. Kojima, N. Takaoka, and Y. Nagayoshi Coronary plaque component in patients with vasospastic angina: a virtual histology intravascular ultrasound study Int J Cardiol 168 3 Oct 3 2013 2411 2415
10. M.H. Yoon, M. Reriani, G. Mario, C. Rihal, R. Gulati, and R. Lennon Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis Int J Cardiol 168 2 Sep 30 2013 1316 1321
11. A. Nakagomi, Y. Saiki, M. Kosugi, K. Kohashi, Y. Yoshikawa, and Y. Yamane Effect of insulin resistance associated with compensatory hyperinsulinemia on the long-term prognosis in patients with vasospastic angina Int J Cardiol 167 5 Sep 1 2013 2222 2227
12. F. Perticone, R. Maio, M. Perticone, S. Miceli, A. Sciacqua, and E.J. Tassone Endothelial dysfunction predicts regression of hypertensive cardiac mass Int J Cardiol 167 4 Aug 20 2013 1188 1192
13. Y. Minami, H. Kaneda, M. Inoue, M. Ikutomi, T. Morita, and T. Nakajima Endothelial dysfunction following drug-eluting stent implantation: a systematic review of the literature Int J Cardiol 165 2 May 10 2013 222 228
14. A.W. Schoenenberger, S. Felber, S. Gujer, A. Moser, P. Jamshidi, and A.E. Stuck Invasive findings in patients with angina equivalent symptoms but no coronary artery disease; results from the heart quest cohort study Int J Cardiol 167 1 Jul 15 2013 168 173
15. Y. Shi, G. Savarese, P. Perrone-Filardi, T.F. Lüscher, and G.G. Camici Enhanced age-dependent cerebrovascular dysfunction is mediated by adaptor protein p66(Shc.) Int J Cardiol 175 3 Aug 20 2014 446 450
16. P. Song, H.S. Sekhon, A. Lu, J. Arredondo, D. Sauer, and C. Gravett M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogenactivated protein kinase phosphorylation induced by acetylcholine secretion Cancer Res 67 8 Apr 15 2007 3936 3944
17. N. Hua, X. Wei, X. Liu, X. Ma, X. He, and R. Zhuo A novel muscarinic antagonist R2HBJJ inhibits non-small cell lung cancer cell growth and arrests the cell cycle in G0/G1 PLoS One 7 12 2012 e53170
18. Y. Liu, S. Wang, C. Wang, H. Song, H. Han, and P. Hang Upregulation of Mâ muscarinic receptor inhibits cardiac hypertrophy induced by angiotensin II J Transl Med 11 Sep 12 2013 209
19. R.D. Harvey Muscarinic receptor agonists and antagonists: effects on cardiovascular function Handb Exp Pharmacol 208 2012 299 316
20. 2 + handling as a common mechanism Can J Physiol Pharmacol 86 2008 860 865
21. 3 muscarinic acetylcholinereceptors has cardioprotective effects against ischaemia-induced arrhythmias Clin Exp Pharmacol Physiol 39 2012 343 349
22. 3 receptor in aconitine/barium-chloride-induced preconditioning against arrhythmias in rats Naunyn Schmiedebergs Arch Pharmacol 379 2009 511 515
23. H. Shi, H. Wang, B. Yang, D. Xu, and Z. Wang The M3 receptor-mediated K(+) current (IKM3), a G(q) protein-coupled K(+) channel J Biol Chem 279 21 May 21 2004 21774 21778
24. H. Wang, Y. Lu, and Z. Wang Function of cardiac M3 receptors Auton Autacoid Pharmacol 27 1 Jan 2007 1 11 [in review]
25. K.E. Brack, J. Winter, and G.A. Ng Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation - tentative prophylactic properties of vagus nerve stimulation on malignant arrhythmias in heart failure Heart Fail Rev 18 4 Jul 2013 389 408
26. Y. Liu, C.Q. Xu, J.D. Jiao, H.Z. Wang, and D.L. Dong Yang BF M3-R/IK(M3) - a new target of antiarrhythmic agents Yao Xue Xue Bao 40 1 Jan 2005 8 12
27. D.L. Jones, J.M. Tuomi, and P. Chidiac Role of Cholinergic Innervation and RGS2 in Atrial Arrhythmia Front Physiol 3 Jun 29 2012 239
28. 3-muscarinic acetylcholine receptors remodeling in patients with a dilated atrium Acta Cardiol 63 2008 166 170
29. + channels in canine atria with atrial fibrillation induced by experimental congestive heart failure Cell Physiol Biochem 14 2004 31 40
30. K.E. Andersson, L. Campeau, and B. Olshansky Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction Br J Clin Pharmacol 72 2 Aug 2011 186 196
31. Z. Pan, Y. Guo, H. Qi, K. Fan, S. Wang, and H. Zhao M3 subtype of muscarinic acetylcholine receptor promotes cardioprotection via the suppression of miR-376b-5p PLoS One 7 3 2012 e32571
32. P. ZHANG, D.C. XIANG, Q.I.U.J. DEN QN, and X.M. HE Relationship between expression of acetylcholine muscarinic 2 and 3 receptors on peripheral blood lymphocytes in patients and coronary artery spasm [J] J Clin Med Pract 3 2009 010
33. 3 receptors in response to acetylcholine Arterioscler Thromb Vasc Biol 24 2004 1253 1258
34. N. Harada, K. Ochi, N. Yaosaka, H. Teraoka, T. Hiraga, and T. Iwanaga Immunohistochemical and functional studies for Mâ muscarinic receptors and cyclo-oxygenase-2 expressed in the mouse atrium Auton Autacoid Pharmacol 32 3 Pt 4 Oct 2012 41 52
35. J. Hu, K. Hu, T. Liu, M.K. Stern, R. Mistry, and R.A. Challiss Novel structural and functional insights into M3 muscarinic receptor dimer/oligomer formation J Biol Chem 288 48 Nov 29 2013 34777 34790
36. S.M. McMillin, M. Heusel, T. Liu, S. Costanzi, and J. Wess Structural basis of M3 muscarinic receptor dimer/oligomer formation J Biol Chem 286 32 Aug 12 2011 28584 28598
37. H. Deng, H. Sun, and Y. Fang Label-free cell phenotypic assessment of the biased agonism and efficacy of agonists at the endogenous muscarinic M3 receptors J Pharmacol Toxicol Methods 68 3 Nov-Dec 2013 323 333
38. J. Hu, D. Thor, Y. Zhou, T. Liu, Y. Wang, and S.M. McMillin Structural aspects of Mâ muscarinic acetylcholine receptor dimer formation and activation FASEB J 26 2 Feb 2012 604 616
39. S. Patanè The emerging scenario of the onco-cardiovascular patients J Cardiol Ther 1 8 2014 141 149
40. E. Conti, A. Romiti, M.B. Musumeci, J. Passerini, L. Zezza, and V. Mastromarino Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors Int J Cardiol 167 6 Sep 10 2013 2421 2429
41. S. Rateesh, S.A. Luis, C.R. Luis, B. Hughes, and M. Nicolae Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge Int J Cardiol 172 2 Mar 15 2014 e331 e333
42. S. Kurisu, T. Iwasaki, K. Ishibashi, N. Mitsuba, Y. Dohi, and Y. Kihara Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients Int J Cardiol 167 5 Sep 1 2013 2335 2337
43. J.M. Scott, L.W. Jones, W.E. Hornsby, G.J. Koelwyn, M.G. Khouri, and A.A. Joy Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training Int J Cardiol 171 2 Feb 1 2014 e50 e51
44. S. Claridge, A. Chakrabarti, K. Greaves, and C.J. Boos Successful use of trastuzumab following cardiac resynchronisation therapy Int J Cardiol 166 2 Jun 20 2013 e33 e34
45. M. Lotrionte, G. Palazzoni, A. Abbate, E. De Marco, E. Mezzaroma, and S. Di Persio Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue doppler imaging Evaluation) randomized pilot study Int J Cardiol 167 3 Aug 10 2013 1055 1057
46. M.G. Kaya, M. Ozkan, O. Gunebakmaz, H. Akkaya, E.G. Kaya, and M. Akpek Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study Int J Cardiol 167 5 Sep 1 2013 2306 2310
47. Y. Ozkanlar, M.S. Aktas, M. Turkeli, N. Erturk, E. Oruc, and S. Ozkanlar Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity Int J Cardiol 173 3 May 15 2014 519 521
48. Y.F. Hu, C.J. Liu, P.M. Chang, H.M. Tsao, Y.J. Lin, and S.L. Chang Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients Int J Cardiol 165 2 May 10 2013 355 357
49. A. Budaj-Fidecka, M. Kurzyna, A. Fijałkowska, J. Żyłkowska, M. Wieteska, and M. Florczyk In-hospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL Registry data Int J Cardiol 168 4 Oct 9 2013 3543 3549
50. P. Pugliatti, R. Donato, G. Di Bella, S. Carerj, and S. Patanè Contrast-enhancing right atrial thrombus in cancer patient Int J Cardiol 173 3 May 15 2014 e35 e37
51. S. Grover, D.P. Leong, A. Chakrabarty, L. Joerg, D. Kotasek, and K. Cheong Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers Int J Cardiol 168 6 Oct 15 2013 5465 5467
52. W. Jurczak, S. Szmit, M. Sobociński, M. Machaczka, J. Drozd-Sokołowska, and M. Joks Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study Int J Cardiol 168 6 Oct 15 2013 5212 5217
53. Lestuzzi C. Cardioncology Oncocardiology. Are we barking up the wrong tree? Int J Cardiol 167 2 Jul 31 2013 307 309
54. P. Pugliatti, R. Donato, C. Zito, S. Carerj, and S. Patanè Cardio inhibitory vasovagal syncope in a cancer patient Int J Cardiol 174 2 Jun 15 2014 e64 e65
55. P. Pugliatti, C. De Gregorio, and S. Patanè The chance finding of echocardiographic complications of infective endocarditis Int J Cardiol 161 3 Nov 29 2012 e50 e51
56. S. Patanè Breast cancer treatment cardioprotective strategies: the King is naked J Am Heart Assoc July 22 2014 [2014 to be Published. http://www.jaha.ahajournals.org/content/3/2/e000665/reply ]
57. Y. Elkina, S. Palus, A. Tschirner, K. Hartmann, S. von Haehling, and W. Doehner Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia Int J Cardiol 170 2 Dec 10 2013 160 166
58. J. Springer, A. Tschirner, K. Hartman, S. von Haehling, S.D. Anker, and W. Doehner The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy Int J Cardiol 168 4 Oct 9 2013 3527 3531
59. S. Palus, S. von Haehling, V.C. Flach, A. Tschirner, W. Doehner, and S.D. Anker Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia Int J Cardiol 168 4 Oct 9 2013 3412 3418
60. V. Avbelj, and R. Trobec A closer look at electrocardiographic P waves before and during spontaneous cardioinhibitory syncope Int J Cardiol 166 3 Jul 1 2013 e59 e61
61. W.J. Jang, H.R. Yim, S.H. Lee, S.J. Park, J.S. Kim, and Y.K. On Prognosis after tilt training in patients with recurrent vasovagal syncope Int J Cardiol 168 4 Oct 9 2013 4264 4265
62. K.P. Loh, and O. Ogunneye Malignant cardioinhibitory vasovagal syncope - an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome!Int J Cardiol 164 3 Apr 15 2013 e38 e39
63. S. Patanè, and F. Marte Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system Eur Heart J 30 10 May 2009 1169 1170
64. M. Arcopinto, C.A. Cella, R. Wesolowski, A. Salzano, E. Bossone, and A. Cittadini Primary prevention of cancer-related thrombosis: special focus on ambulatory patients Int J Cardiol 173 3 May 15 2014 583 584
65. S. Patanè, and F. Marte Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going? Int J Cardiol 146 1 Jan 7 2011 e20 e22
66. S. Patanè, and F. Marte Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario Int J Cardiol 134 3 May 29 2009 e147 e149
67. S. Patanè Prostate-specific antigen kallikrein and the heart World J Cardiol 1 1 Dec 31 2009 23 25
68. G.M. Calvagna, and S. Patanè Transvenous pacemaker lead extraction in infective endocarditis Int J Cardiol 176 2 Sept 20 2014 511 513
69. S. Patanè Cancer multidrug resistance-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs Int J Cardiol 176 3 Oct 20 2014 1306 1308
70. S. Patanè HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs Int J Cardiol 176 3 Oct 20 2014 1082 1085
71. S. Patanè Cardiotoxicity: cisplatin and long term cancer survivors Int J Cardiol 175 1 Jul 15 2014 201 202
72. S. Patanè Cardiotoxicity: Anthracyclines and long term cancer survivors Int J Cardiol 176 3 Oct 20 2014 1326 1328
73. S. Patanè Cardiotoxicity: Trastuzumab and cancer survivors Int J Cardiol 177 2 Aug 26 2014 554 556
74. S. Patanè Ebola: is there a hope from treatment with cardiovascular drugs? Int J Cardiol 177 2 Aug 26 2014 524 526
75. S. Patanè ERBB1/EGFR and ERBB2 (HER2/neu) - targeted therapies in cancer and cardiovascular system with cardiovascular drugs Int J Cardiol 176 3 Oct 20 2014 1301 1303
76. S. Patanè A challenge in cardiology: the oncosurgery Int J Cardiol 174 2 2014 Jun 15 411 412
77. S. Patanè Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer Curr Med Res Opin Jun 26 2014 1 2
78. S. Patanè Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies J Card Fail 20 6 Jun 2014 456 457
79. S. Patanè Is there a role for quinazoline-based α(1)-adrenoceptor antagonists in cardio-oncology? Cardiovasc Drugs Ther Sep 18 2014 [Epub ahead of print]
80. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J Cardiovasc Transl Res 7 3 Apr 2014 369 371
81. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing gastrointestinal endoscopy? J Cardiovasc Transl Res 7 3 Apr 2014 372 374
82. R. La Rocca, G. Ferrari-Toninelli, and S. Patanè Widened QRS interval and left ventricular systolic depression after propafenone and promazine exposure Int J Cardiol 177 1 Nov 15 2014 57 60
83. P. Pugliatti, A. Recupero, C. Zito, and S. Patanè The chance finding of an atrial septal defect in a cancer patient Int J Cardiol 2014 [accepted for publication]
84. Z.P. Xu, K. Yang, G.N. Xu, L. Zhu, L.N. Hou, and W.H. Zhang Role of M3 mAChR in in vivo and in vitro models of LPS-induced inflammatory response Int Immunopharmacol 14 3 Nov 2012 320 327
85. A.J. Español, M.O. Maddaleno, M.G. Lombardi, M. Cella, P. Martínez Pulido, and M.E. Sales Treatment with lipopolysaccharide plus interferon γ induces the expression and function of muscarinic acetylcholine receptors, modulating NIH3T3 cell proliferation. Participation of nitric oxide synthase and cyclooxygenase Br J Pharmacol 171 22 Nov 5 2014 5154 5167
86. Y.J. Feng, B.Y. Zhang, R.Y. Yao, and Y. Lu Muscarinic acetylcholine receptor M3 in proliferation and perineural invasion of cholangiocarcinoma cells Hepatobiliary Pancreat Dis Int 11 4 Aug 15 2012 418 423
87. F.Z. Shen, B.Y. Zhang, Y.J. Feng, Z.X. Jia, B. An, and C.C. Liu Current research in perineural invasion of cholangiocarcinoma J Exp Clin Cancer Res 29 24 Mar 10 2010
88. C.M. Zhao, Y. Hayakawa, Y. Kodama, S. Muthupalani, C.B. Westphalen, and G.T. Andersen Denervation suppresses gastric tumorigenesis Sci Transl Med 6 250 Aug 20 2014 250ra115
89. E.C. von Rosenvinge, K. Cheng, C.B. Drachenberg, C.B. Fowler, D.L. Evers, and G. Xie Bedside to bench: role of muscarinic receptor activation in ultrarapid growth of colorectal cancer in a patient with pheochromocytoma Mayo Clin Proc 88 11 Nov 2013 1340 1346
90. K. Yang, Y. Song, Y.B. Tang, Z.P. Xu, W. Zhou, and L.N. Hou mAChRs activation induces epithelial-mesenchymal transition on lung epithelial cells BMC Pulm Med 14 Mar 31 2014 53
91. W. Song, M. Yuan, and S. Zhao Variation of M3 muscarinic receptor expression in different prostate tissues and its significance Saudi Med J 30 8 Aug 2009 1010 1016
92. V.A. Barathi, S.R. Weon, and R.W. Beuerman Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation Mol Vis 15 Jun 30 2009 1277 1293
93. G. Xie, K. Cheng, J. Shant, and J.P. Raufman Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells Am J Physiol Gastrointest Liver Physiol 296 4 Apr 2009 G755 G763
94. K. Cheng, and J.P. Raufman Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors Biochem Pharmacol 70 7 Oct 1 2005 1035 1047
95. K. Cheng, P. Zimniak, and J.P. Raufman Transactivation of the epidermal growth factor receptor mediates cholinergic agonist-induced proliferation of H508 human colon cancer cells Cancer Res 63 20 Oct 15 2003 6744 6750
96. A. Belo, K. Cheng, A. Chahdi, J. Shant, G. Xie, and S. Khurana Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion Am J Physiol Gastrointest Liver Physiol 300 5 May 2011 G749 G760
97. T. Wang, A. Hogan-Cann, Y. Kang, Z. Cui, J. Guo, and T. Yang Muscarinic receptor activation increases hERG channel expression through phosphorylation of ubiquitin ligase Nedd4-2 Mol Pharmacol 85 6 Jun 2014 877 886